公开(公告)号：US20240207224A1

公开(公告)日：2024-06-27

申请号：US18509403

申请日：2023-11-15

Applicant: ENANTA PHARMACEUTICALS, INC.

Inventor： Jiajun Zhang ,  Xuri Gao ,  Hui Cao ,  Yuk Ming Siu ,  Bin Wang ,  Jiang Long ,  Wei Li ,  Matthew C. Rhodes ,  Xuechao Xing ,  Scott Mitchell ,  Yat Sun Or

IPC: A61K31/395 ,  A61K31/4192 ,  A61K31/4995 ,  A61P31/14 ,  C07D225/04 ,  C07D245/04 ,  C07D255/04 ,  C07D273/02 ,  C07D281/00 ,  C07D285/00 ,  C07D487/08

CPC classification number: A61K31/395 ,  A61K31/4192 ,  A61K31/4995 ,  A61P31/14 ,  C07D225/04 ,  C07D245/04 ,  C07D255/04 ,  C07D273/02 ,  C07D281/00 ,  C07D285/00 ,  C07D487/08

Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, thereof:




which inhibit coronavirus replication activity. The invention further relates to pharmaceutical compositions comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof, and methods of treating or preventing a coronavirus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof.

公开(公告)号：US20230357258A1

公开(公告)日：2023-11-09

申请号：US18131405

申请日：2023-04-06

Applicant: ENANTA PHARMACEUTICALS, INC.

Inventor： Adam Szymaniak ,  Robert Leon ,  Kevin McGrath ,  Xiben Li ,  Tyler J. Mann ,  Jianming Yu ,  In Jong Kim ,  Scott Mitchell ,  Yat Sun Or

IPC: C07D491/048 ,  A61P31/14 ,  A61K45/06 ,  C07D519/00

CPC classification number: C07D491/048 ,  A61P31/14 ,  A61K45/06 ,  C07D519/00 ,  C07B2200/05

Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, esters, or prodrugs thereof:




which inhibit Human Respiratory Syncytial Virus (HRSV) or Human Metapneumovirus (HMPV) inhibitors. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HRSV or HMPV infection. The invention also relates to methods of treating an HRSV or HMPV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

公开(公告)号：US20240140922A1

公开(公告)日：2024-05-02

申请号：US18236560

申请日：2023-08-22

Applicant: ENANTA PHARMACEUTICALS, INC.

Inventor： Samuel Bartlett ,  Joseph D. Panarese ,  Sourav Ghorai ,  Nathaniel Thomas Kenton ,  Sean Rafferty ,  Jonathan Thielman ,  Peilin Xu ,  Bin Wang ,  William Cassels ,  Scott Mitchell ,  Yat Sun Or

IPC: C07D285/36 ,  A61P31/20 ,  C07D337/08 ,  C07D417/04 ,  C07D417/08 ,  C07D417/12 ,  C07D417/14 ,  C07D487/04 ,  C07D513/04 ,  C07F9/6536

CPC classification number: C07D285/36 ,  A61P31/20 ,  C07D337/08 ,  C07D417/04 ,  C07D417/08 ,  C07D417/12 ,  C07D417/14 ,  C07D487/04 ,  C07D513/04 ,  C07F9/6536

Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, thereof:




which inhibit the cellular entry of hepatitis B virus (HBV) and/or hepatitis D virus (HDV) or interfere with the function of the life cycle of HBV and/or HDV and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV and/or HDV infection. The invention also relates to methods of treating an HBV and/or HDV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.